A protein comprising two heterodimers, wherein each heterodimer comprises: a) a first polypeptide, comprising, in order from N-terminus to C-terminus: i) a human papilloma virus 16 E7 epitope comprising the amino acid sequence: YMLDLQPETT (SEQ ID NO: 13); ii) a first linker, comprising the amino acid sequence: GGGGSGGGGSGGGGS (SEQ ID NO: 89); and iii) a β2-microglobulin (β2M) polypeptide, comprising the amino acid sequence as set forth in SEQ ID NO: 17; and b) a second polypeptide, comprising in order from N-terminus to C-terminus: i) a first variant IL-2 polypeptide, comprising the amino acid sequence as set forth in SEQ ID NO: 84; ii) a second linker, comprising the amino acid sequence: GGGGSGGGGSGGGGSGGGGS (SEQ ID NO:90); iii) a second variant IL-2 polypeptide, comprising the amino acid sequence as set forth in SEQ ID NO: 84; iv) a third linker, comprising the amino acid sequence: GGGGSGGGGSGGGGSGGGGS (SEQ ID NO:90); v) a class I MHC heavy chain polypeptide, comprising the amino acid sequence as set forth in SEQ ID NO: 19; vi) a fourth linker, comprising the amino acid sequence AAAGG (SEQ ID NO:28); and vii) a variant immunoglobulin (Ig) G1 Fc polypeptide, comprising a first leucine to alanine substitution at a position corresponding with position 14 of the human IgG1 Fc sequence set forth in SEQ ID NO:80 (L14A); and a second L to A substitution at a position corresponding with position 15 of the human IgG1 Fc sequence set forth in SEQ ID NO:80 (L15A); wherein the first polypeptide and the second polypeptide of each heterodimer are covalently linked to one another via a disulfide bond between the Cys residue at amino acid 12 of the β2M polypeptide and the Cys residue at amino acid 236 of the class I MHC heavy chain polypeptide, and wherein the two heterodimers are joined to each other by one or more disulfide bonds that join the variant immunoglobulin Fc polypeptide of one heterodimer to the variant immunoglobulin Fc polypeptide of the other heterodimer. a) a first polypeptide, comprising, in order from N-terminus to C-terminus: i) a human papilloma virus 16 E7 epitope comprising the amino acid sequence: YMLDLQPETT (SEQ ID NO: 13); ii) a first linker, comprising the amino acid sequence: GGGGSGGGGSGGGGS (SEQ ID NO: 89); and iii) a β2-microglobulin (β2M) polypeptide, comprising the amino acid sequence as set forth in SEQ ID NO: 17; and i) a human papilloma virus 16 E7 epitope comprising the amino acid sequence: YMLDLQPETT (SEQ ID NO: 13); ii) a first linker, comprising the amino acid sequence: GGGGSGGGGSGGGGS (SEQ ID NO: 89); and iii) a β2-microglobulin (β2M) polypeptide, comprising the amino acid sequence as set forth in SEQ ID NO: 17; and b) a second polypeptide, comprising in order from N-terminus to C-terminus: i) a first variant IL-2 polypeptide, comprising the amino acid sequence as set forth in SEQ ID NO: 84; ii) a second linker, comprising the amino acid sequence: GGGGSGGGGSGGGGSGGGGS (SEQ ID NO:90); iii) a second variant IL-2 polypeptide, comprising the amino acid sequence as set forth in SEQ ID NO: 84; iv) a third linker, comprising the amino acid sequence: GGGGSGGGGSGGGGSGGGGS (SEQ ID NO:90); v) a class I MHC heavy chain polypeptide, comprising the amino acid sequence as set forth in SEQ ID NO: 19; vi) a fourth linker, comprising the amino acid sequence AAAGG (SEQ ID NO:28); and vii) a variant immunoglobulin (Ig) G1 Fc polypeptide, comprising a first leucine to alanine substitution at a position corresponding with position 14 of the human IgG1 Fc sequence set forth in SEQ ID NO:80 (L14A); and a second L to A substitution at a position corresponding with position 15 of the human IgG1 Fc sequence set forth in SEQ ID NO:80 (L15A); i) a first variant IL-2 polypeptide, comprising the amino acid sequence as set forth in SEQ ID NO: 84; ii) a second linker, comprising the amino acid sequence: GGGGSGGGGSGGGGSGGGGS (SEQ ID NO:90); iii) a second variant IL-2 polypeptide, comprising the amino acid sequence as set forth in SEQ ID NO: 84; iv) a third linker, comprising the amino acid sequence: GGGGSGGGGSGGGGSGGGGS (SEQ ID NO:90); v) a class I MHC heavy chain polypeptide, comprising the amino acid sequence as set forth in SEQ ID NO: 19; vi) a fourth linker, comprising the amino acid sequence AAAGG (SEQ ID NO:28); and vii) a variant immunoglobulin (Ig) G1 Fc polypeptide, comprising a first leucine to alanine substitution at a position corresponding with position 14 of the human IgG1 Fc sequence set forth in SEQ ID NO:80 (L14A); and a second L to A substitution at a position corresponding with position 15 of the human IgG1 Fc sequence set forth in SEQ ID NO:80 (L15A); wherein the first polypeptide and the second polypeptide of each heterodimer are covalently linked to one another via a disulfide bond between the Cys residue at amino acid 12 of the β2M polypeptide and the Cys residue at amino acid 236 of the class I MHC heavy chain polypeptide, and wherein the two heterodimers are joined to each other by one or more disulfide bonds that join the variant immunoglobulin Fc polypeptide of one heterodimer to the variant immunoglobulin Fc polypeptide of the other heterodimer.